by Paul | 21st July 2026 | News
London and New York, NY, July 21, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that its...
by Paul | 20th July 2026 | News
London and New York, NY, July 20, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced the...
by Paul | 8th July 2026 | News
FDA alignment on a single-dose Phase 3 study design and potential single-trial registration pathway further strengthens the Company’s clinical development program for urcosimod Company unveils NEPTUNE (Neuropathic Eye Pain Treatment with Urcosimod & Nerve...
by Paul | 7th July 2026 | News
London and New York, NY, July 7, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced...
by Paul | 19th May 2026 | News
Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative disease OKYO’s introduction to the broader ophthalmology community at ASCRS drove strong engagement at Eyecelerator and ARVO London and New...
